Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Chia

Showing results (201-210 of 256) with videos related to

Pageof 26
Sort By:
Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.
Annals of the Academy of Medicine, Singapore|December 7, 2020
Cancer Versus COVID-19: A Coordinated Disease Outbreak Response System (DORS) to Combat COVID-19 at the National Cancer Centre SingaporeRavindran Kanesvaran, Claramae S Chia, Swee Peng Yap, et al.
Diabetologia|October 6, 2006
Ethnicity modifies the association between diabetes mellitus and ischaemic heart disease in Chinese, Malays and Asian Indians living in SingaporeK K Yeo, B C Tai, D Heng, et al.
Current Oncology (Toronto, Ont.)|February 17, 2015
Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancerS Chia, S Gandhi, A A Joy, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.
Annals of the Academy of Medicine, Singapore|April 14, 2012
2011 Young Surgeon's Award Winner: high endothelial venules: a novel prognostic marker in cancer metastasis and the missing link?Ser Yee Lee, Chao Nan Qian, Aik Seng Ooi, et al.
Breast Cancer Research : BCR|November 30, 2006
Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up studyKristjana Einarsdóttir, Lena U Rosenberg, Keith Humphreys, et al.
Current Oncology (Toronto, Ont.)|October 25, 2013
Benefits, issues, and recommendations for personalized medicine in oncology in CanadaC Butts, S Kamel-Reid, G Batist, et al.
Pediatric Nephrology (Berlin, Germany)|September 1, 1990
Acute glomerulonephritis--changing patterns in Singapore childrenH K Yap, K S Chia, B Murugasu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)A Schneeweiss, S Chia, T Hickish, et al.
Pageof 26

Showing results (201-210 of 256) with videos related to

Sort By:
Pageof 26
Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.
Annals of the Academy of Medicine, Singapore|December 7, 2020
Cancer Versus COVID-19: A Coordinated Disease Outbreak Response System (DORS) to Combat COVID-19 at the National Cancer Centre SingaporeRavindran Kanesvaran, Claramae S Chia, Swee Peng Yap, et al.
Diabetologia|October 6, 2006
Ethnicity modifies the association between diabetes mellitus and ischaemic heart disease in Chinese, Malays and Asian Indians living in SingaporeK K Yeo, B C Tai, D Heng, et al.
Current Oncology (Toronto, Ont.)|February 17, 2015
Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancerS Chia, S Gandhi, A A Joy, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.
Annals of the Academy of Medicine, Singapore|April 14, 2012
2011 Young Surgeon's Award Winner: high endothelial venules: a novel prognostic marker in cancer metastasis and the missing link?Ser Yee Lee, Chao Nan Qian, Aik Seng Ooi, et al.
Breast Cancer Research : BCR|November 30, 2006
Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up studyKristjana Einarsdóttir, Lena U Rosenberg, Keith Humphreys, et al.
Current Oncology (Toronto, Ont.)|October 25, 2013
Benefits, issues, and recommendations for personalized medicine in oncology in CanadaC Butts, S Kamel-Reid, G Batist, et al.
Pediatric Nephrology (Berlin, Germany)|September 1, 1990
Acute glomerulonephritis--changing patterns in Singapore childrenH K Yap, K S Chia, B Murugasu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2013
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)A Schneeweiss, S Chia, T Hickish, et al.
Pageof 26